New data on adjuvant therapy for breast cancer.

被引：0
作者：
Wolff A.C. [1 ]
Davidson N.E. [1 ]
机构：
[1] Division of Medical Oncology, Room 130, The Johns Hopkins Oncology Center, 600 North Wolfe Street, Baltimore, 21287, MD
来源：
Current Oncology Reports | 1999年 / 1卷 / 1期
关键词：
Breast Cancer; Tamoxifen; Sentinel Node Biopsy; Operable Breast Cancer; Proc ASCO;
D O I：
10.1007/s11912-999-0007-5
中图分类号：
学科分类号：
摘要：
In the past year, the results of the third Oxford Overview and recommendations from the St. Gallen International Consensus Panel on adjuvant treatment for breast cancer were published. Reports of trials addressing the role of anthracyclines and taxanes, as well as the optimal dosing schedule for cyclophosphamide, methotrexate, and 5-fluorouracil, also appeared. Data show that primary therapy increases the rate of breast conservation but not survival rates. The initial results of trials of high-dose chemotherapy with autologous hematopoietic support have been mixed. The usefulness of sentinel node biopsy in minimizing surgical morbidity and of biologic markers in predicting response to adjuvant therapy are areas of active research.
引用
收藏
页码：31 / 37
页数：6
相关论文
共 116 条
[1]  
Goldhirsch A(1998)Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer J Natl Cancer Inst 90 1601-1608
[2]  
Glick JH(1999)Low proliferative rate of invasive node negative breast cancer predicts for a favorable outcome without adjuvant chemotherapy [abstract] Proc ASCO 18 70a-70a
[3]  
Gelber RD(1999)Favorable biological characteristics and clinical outcome in elderly patients with invasive ductal carcinoma (IDC) of the breast [abstract] Proc ASCO 18 70a-70a
[4]  
Senn HJ(1998)CMF versus CAF with and without tamoxifen in high-risk node-negative breast cancer patients and a natural history follow-up study in low-risk node-negative patients: first results of intergroup trial INT 0102 [abstract] Proc ASCO 17 1a-1a
[5]  
Jones S(1998)The sentinel node in breast cancer—a multicenter validation study N Engl J Med 339 941-946
[6]  
Clark G(1998)Sentinellymph-node biopsy for breast cancer—not yet the standard of care N Engl J Med 339 990-995
[7]  
Koleszar S(1997)HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas J Clin Oncol 15 2894-2904
[8]  
Diab SG(1998)HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study Clin Cancer Res 4 7-12
[9]  
Elledge RM(1999)Results of prolonged adjuvant tamoxifen therapy of breast cancer correlated to steroid receptor, S-phase and ERBB2 levels [abstract] Proc ASCO 18 70a-70a
[10]  
Clark GM(1998)Initial report of the SWOG biological correlative study of c-erbB-2 expression as a predictor of outcome in a trial comparing adjuvant CAFT with tamoxifen (T) alone [abstract] Proc ASCO 17 97a-97a
12345678910